 Home > Active Ingredient News > Blood System > Express $1.1 billion capsule received Phase 2/3 clinical therapy, Novo Nordisk expands the blood disease pipeline

Express $1.1 billion capsule received Phase 2/3 clinical therapy, Novo Nordisk expands the blood disease pipeline

 Last Update: 2022-09-06
 Source: Internet
 Author: User

▎ WuXi AppTec content team editor

Novo Nordisk today announced a $1.

▲ Etavopivat molecular structural formula (Image source: PubChem)

Etavopivat is currently examining its efficacy and safety

[1] Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

SULODEXIDE 99% Almost White Powder Dideu-01112 Dideu

CAS No.: 57821-29-1

Pharmacy Grade

$61.76/G EXW

Heparin sodium 9041-08-1 vials safe delivery

CAS No.: 9041-08-1

Pharmacy Grade

$1/G EXW

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.